|
gptkbp:instance_of
|
gptkb:genus
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Herpesviridae
|
|
gptkbp:associated_with
|
latent infection
|
|
gptkbp:caused_by
|
gptkb:roseola
cytomegalovirus disease
immunocompromised complications
|
|
gptkbp:contains
|
gptkb:Human_herpesvirus_6
gptkb:Human_herpesvirus_7
gptkb:Human_cytomegalovirus
gptkb:Murine_cytomegalovirus
|
|
gptkbp:data_usage
|
high in immunocompromised individuals
|
|
gptkbp:faculties
|
icosahedral
|
|
gptkbp:family
|
gptkb:Herpesviridae
|
|
gptkbp:has_distribution
|
gptkb:theorem
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Beta herpesvirinae
|
|
gptkbp:includes
|
several human pathogens
|
|
gptkbp:is_characterized_by
|
large, complex genome
slow replication
|
|
gptkbp:is_found_in
|
gptkb:Person
mice
|
|
gptkbp:is_known_for
|
latency in host cells
|
|
gptkbp:is_part_of
|
gptkb:Herpesviridae
|
|
gptkbp:is_recognized_by
|
1960s
|
|
gptkbp:is_related_to
|
gptkb:Gamma_herpesvirinae
Alpha herpesvirinae
|
|
gptkbp:is_studied_in
|
virology
|
|
gptkbp:is_vulnerable_to
|
no widely available vaccine
|
|
gptkbp:propagation_method
|
direct contact
bodily fluids
|
|
gptkbp:range
|
wide range of mammals
|
|
gptkbp:research_focus
|
vaccine development
antiviral therapies
|
|
gptkbp:seed_dispersal
|
approximately 230-240 kb
|
|
gptkbp:size
|
120-200 nm
|
|
gptkbp:symptoms
|
fatigue
fever
rash
|
|
gptkbp:treatment
|
supportive care
antiviral medications
|
|
gptkbp:type_of
|
double-stranded DNA virus
|
|
gptkbp:wildlife
|
low
|